Leap Therapeutics Inc LPTX:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/12/2022
Last Price$1.30NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/11/22

Today's Change+0.13(11.11%)
Bid (Size)$1.15 (10)
Ask (Size)$1.76 (6)
Day Low / High$1.16 - 1.38
Volume1.2 M
 

View Biotechnology IndustryPeer Comparison as of 08/11/2022

 

Leap Therapeutics Inc ( NASDAQ )

Price: $1.30
Change: +0.13 (11.11%)
Volume: 1.2 M
4:00PM ET 8/11/2022
 
 

AquaBounty Technologies Inc ( NASDAQ )

Price: $1.44
Change: +0.01 (0.70%)
Volume: 623.0 K
4:00PM ET 8/11/2022
 
 

Surface Oncology Inc ( NASDAQ )

Price: $1.85
Change: +0.04 (2.21%)
Volume: 306.00
4:00PM ET 8/11/2022
 
 

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $2.95
Change: +0.04 (1.37%)
Volume: 103.8 K
3:59PM ET 8/11/2022
 
 

Seelos Therapeutics Inc ( NASDAQ )

Price: $0.91
Change: -0.02 (2.53%)
Volume: 516.7 K
4:00PM ET 8/11/2022
 

Read more news Recent News

Raymond James Adjusts Leap Therapeutics' Price Target to $3 from $4, Keeps Outperform Rating
11:06AM ET 7/13/2022 MT Newswires

Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $3 to $6, according to analysts polled by Capital IQ. (MT...

Leap Therapeutics, BeiGene Initiate New DKN-01 Trials for Cancers
7:47AM ET 7/12/2022 MT Newswires

Leap Therapeutics (LPTX) and BeiGene, Ltd (BGNE) said Tuesday that they have initiated Part C of an ongoing study on Leap's treatment DKN-01 in combination...

Piper Sandler Adjusts Leap Therapeutics' Price Target to $4 From $6, Reiterates Overweight Rating
5:14AM ET 5/31/2022 MT Newswires

Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $4 to $6, according to analysts polled by Capital IQ. (MT...

Leap Therapeutics, Leica Team Up to Develop Companion Diagnostic for Cancer Patients
7:51AM ET 1/31/2022 MT Newswires

Leap Therapeutics (LPTX) said Monday that it has teamed up with Leica Biosystems to develop a companion diagnostic to detect Dickkopf-related protein 1....

Company Profile

Business DescriptionLeap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. View company web site for more details
Address47 Thorndike Street
Cambridge, Massachusetts 02141
Phone+1.617.714.0360
Number of Employees25
Recent SEC Filing07/12/20228-K
President, CEO, CFO, Secretary & TreasurerDoug E. Onsi
Chief Operating OfficerAugustine J. Lawlor
Chief Medical OfficerCynthia Sirard
Head-ResearchMichael Haas

Company Highlights

Price Open$1.18
Previous Close$1.30
52 Week Range$0.92 - 4.17
Market Capitalization$114.8 M
Shares Outstanding88.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/12/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.48
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-3,718.13%
Return on Equity-47.38%

Analyst Ratings as of 05/13/2022

Buy
3
Overweight
2
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset